{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T12:58:42Z","timestamp":1794488322399,"version":"4.9.1"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1038\/s41591-025-03743-2","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T05:01:57Z","timestamp":1748926917000},"page":"2602-2610","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":209,"title":["A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9659-6993","authenticated-orcid":false,"given":"Zuojun","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9157-9182","authenticated-orcid":false,"given":"Feng","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunting","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dedong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghong","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yipeng","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haohui","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6998-9828","authenticated-orcid":false,"given":"Huiping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengming","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinhua","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingchao","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuke","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujata","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Satler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail","family":"Korzinkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8668-3601","authenticated-orcid":false,"given":"David","family":"Gennert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7067-8966","authenticated-orcid":false,"given":"Alex","family":"Zhavoronkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,3]]},"reference":[{"key":"3743_CR1","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/nrd3681","volume":"11","author":"JW Scannell","year":"2012","unstructured":"Scannell, J. W., Blanckley, A., Boldon, H. & Warrington, B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat. Rev. Drug Discov. 11, 191\u2013200 (2012).","journal-title":"Nat. Rev. Drug Discov."},{"key":"3743_CR2","doi-asserted-by":"publisher","first-page":"939","DOI":"10.4155\/fmc-2019-0307","volume":"12","author":"N Berdigaliyev","year":"2020","unstructured":"Berdigaliyev, N. & Aljofan, M. An overview of drug discovery and development. Future Med Chem. 12, 939\u2013947 (2020).","journal-title":"Future Med Chem."},{"key":"3743_CR3","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.tips.2023.06.010","volume":"44","author":"FW Pun","year":"2023","unstructured":"Pun, F. W., Ozerov, I. V. & Zhavoronkov, A. AI-powered therapeutic target discovery. Trends Pharmacol. Sci. 44, 561\u2013572 (2023).","journal-title":"Trends Pharmacol. Sci."},{"key":"3743_CR4","doi-asserted-by":"publisher","first-page":"e17575","DOI":"10.1016\/j.heliyon.2023.e17575","volume":"9","author":"R Qureshi","year":"2023","unstructured":"Qureshi, R. et al. AI in drug discovery and its clinical relevance. Heliyon 9, e17575 (2023).","journal-title":"Heliyon"},{"key":"3743_CR5","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41392-022-00994-0","volume":"7","author":"Y You","year":"2022","unstructured":"You, Y. et al. Artificial intelligence in cancer target identification and drug discovery. Signal Transduct. Target. Ther. 7, 156 (2022).","journal-title":"Signal Transduct. Target. Ther."},{"key":"3743_CR6","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s42256-024-00843-5","volume":"6","author":"Y Du","year":"2024","unstructured":"Du, Y. et al. Machine learning-aided generative molecular design. Nat. Mach. Intell. 6, 589\u2013604 (2024).","journal-title":"Nat. Mach. Intell."},{"key":"3743_CR7","doi-asserted-by":"publisher","first-page":"bbab344","DOI":"10.1093\/bib\/bbab344","volume":"22","author":"Y Cheng","year":"2021","unstructured":"Cheng, Y., Gong, Y., Liu, Y., Song, B. & Zou, Q. Molecular design in drug discovery: a comprehensive review of deep generative models. Brief. Bioinform. 22, bbab344 (2021).","journal-title":"Brief. Bioinform."},{"key":"3743_CR8","doi-asserted-by":"publisher","first-page":"5343","DOI":"10.1021\/acs.jcim.0c01496","volume":"61","author":"T Sousa","year":"2021","unstructured":"Sousa, T., Correia, J., Pereira, V. & Rocha, M. Generative deep learning for targeted compound design. J. Chem. Inf. Model. 61, 5343\u20135361 (2021).","journal-title":"J. Chem. Inf. Model."},{"key":"3743_CR9","doi-asserted-by":"publisher","unstructured":"Ren, F. et al. A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models. Nat. Biotechnol. https:\/\/doi.org\/10.1038\/s41587-024-02143-0 (2024).","DOI":"10.1038\/s41587-024-02143-0"},{"key":"3743_CR10","doi-asserted-by":"publisher","first-page":"8161","DOI":"10.1021\/acs.jmedchem.4c00248","volume":"67","author":"J Xu","year":"2024","unstructured":"Xu, J. et al. Discovery of a novel and potent cyclin-dependent kinase 8\/19 (CDK8\/19) inhibitor for the treatment of cancer. J. Med. Chem. 67, 8161\u20138171 (2024).","journal-title":"J. Med. Chem."},{"key":"3743_CR11","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1002\/cpt.3008","volume":"114","author":"A Aliper","year":"2023","unstructured":"Aliper, A. et al. Prediction of clinical trials outcomes based on target choice and clinical trial design with multi-modal artificial intelligence. Clin. Pharmacol. Ther. 114, 972\u2013980 (2023).","journal-title":"Clin. Pharmacol. Ther."},{"key":"3743_CR12","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1038\/s41591-024-02902-1","volume":"30","author":"S Feuerriegel","year":"2024","unstructured":"Feuerriegel, S. et al. Causal machine learning for predicting treatment outcomes. Nat. Med. 30, 958\u2013968 (2024).","journal-title":"Nat. Med."},{"key":"3743_CR13","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.drudis.2019.12.014","volume":"25","author":"F Feijoo","year":"2020","unstructured":"Feijoo, F., Palopoli, M., Bernstein, J., Siddiqui, S. & Albright, T. E. Key indicators of phase transition for clinical trials through machine learning. Drug Discov. Today 25, 414\u2013421 (2020).","journal-title":"Drug Discov. Today"},{"key":"3743_CR14","doi-asserted-by":"publisher","unstructured":"Artemov, A. V. et al. Integrated deep learned transcriptomic and structure-based predictor of clinical trials outcomes. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/095653 (2016).","DOI":"10.1101\/095653"},{"key":"3743_CR15","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.chembiol.2016.07.023","volume":"23","author":"KM Gayvert","year":"2016","unstructured":"Gayvert, K. M., Madhukar, N. S. & Elemento, O. A data-driven approach to predicting successes and failures of clinical trials. Cell Chem. Biol. 23, 1294\u20131301 (2016).","journal-title":"Cell Chem. Biol."},{"key":"3743_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2024.104133","volume":"29","author":"A Lavecchia","year":"2024","unstructured":"Lavecchia, A. Navigating the frontier of drug-like chemical space with cutting-edge generative AI models. Drug Discov. Today 29, 104133 (2024).","journal-title":"Drug Discov. Today"},{"key":"3743_CR17","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1080\/17460441.2021.1909567","volume":"16","author":"J Jim\u00e9nez-Luna","year":"2021","unstructured":"Jim\u00e9nez-Luna, J., Grisoni, F., Weskamp, N. & Schneider, G. Artificial intelligence in drug discovery: recent advances and future perspectives. Expert Opin. Drug Discov. 16, 949\u2013959 (2021).","journal-title":"Expert Opin. Drug Discov."},{"key":"3743_CR18","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.drudis.2018.11.014","volume":"24","author":"K-K Mak","year":"2019","unstructured":"Mak, K.-K. & Pichika, M. R. Artificial intelligence in drug development: present status and future prospects. Drug Discov. Today 24, 773\u2013780 (2019).","journal-title":"Drug Discov. Today"},{"key":"3743_CR19","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/d41573-022-00025-1","volume":"21","author":"MKP Jayatunga","year":"2022","unstructured":"Jayatunga, M. K. P., Xie, W., Ruder, L., Schulze, U. & Meier, C. AI in small-molecule drug discovery: a coming wave? Nat. Rev. Drug Discov. 21, 175\u2013176 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"3743_CR20","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/biostatistics\/kxx069","volume":"20","author":"CH Wong","year":"2019","unstructured":"Wong, C. H., Siah, K. W. & Lo, A. W. Estimation of clinical trial success rates and related parameters. Biostatistics 20, 273\u2013286 (2019).","journal-title":"Biostatistics"},{"key":"3743_CR21","doi-asserted-by":"publisher","first-page":"104009","DOI":"10.1016\/j.drudis.2024.104009","volume":"29","author":"M KP Jayatunga","year":"2024","unstructured":"KP Jayatunga, M., Ayers, M., Bruens, L., Jayanth, D. & Meier, C. How successful are AI-discovered drugs in clinical trials? A first analysis and emerging lessons. Drug Discov. Today 29, 104009 (2024).","journal-title":"Drug Discov. Today"},{"key":"3743_CR22","doi-asserted-by":"publisher","first-page":"914017","DOI":"10.3389\/fnagi.2022.914017","volume":"14","author":"FW Pun","year":"2022","unstructured":"Pun, F. W. et al. Identification of therapeutic targets for amyotrophic lateral sclerosis using PandaOmics\u2014an AI-enabled biological target discovery platform. Front. Aging Neurosci. 14, 914017 (2022).","journal-title":"Front. Aging Neurosci."},{"key":"3743_CR23","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.18632\/aging.203960","volume":"14","author":"FW Pun","year":"2022","unstructured":"Pun, F. W. et al. Hallmarks of aging-based dual-purpose disease and age-associated targets predicted using PandaOmics AI-powered discovery engine. Aging 14, 2475\u20132506 (2022).","journal-title":"Aging"},{"key":"3743_CR24","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","volume":"198","author":"G Raghu","year":"2018","unstructured":"Raghu, G. et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am. J. Respir. Crit. Care Med. 198, e44\u2013e68 (2018).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"3743_CR25","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMra1705751","volume":"378","author":"DJ Lederer","year":"2018","unstructured":"Lederer, D. J. & Martinez, F. J. Idiopathic pulmonary fibrosis. N. Engl. J. Med. 378, 1811\u20131823 (2018).","journal-title":"N. Engl. J. Med."},{"key":"3743_CR26","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1016\/S0140-6736(17)30866-8","volume":"389","author":"L Richeldi","year":"2017","unstructured":"Richeldi, L., Collard, H. R. & Jones, M. G. Idiopathic pulmonary fibrosis. Lancet 389, 1941\u20131952 (2017).","journal-title":"Lancet"},{"key":"3743_CR27","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.rmed.2017.05.017","volume":"129","author":"G Raghu","year":"2017","unstructured":"Raghu, G. & Richeldi, L. Current approaches to the management of idiopathic pulmonary fibrosis. Respir. Med. 129, 24\u201330 (2017).","journal-title":"Respir. Med."},{"key":"3743_CR28","doi-asserted-by":"publisher","first-page":"17074","DOI":"10.1038\/nrdp.2017.74","volume":"3","author":"FJ Martinez","year":"2017","unstructured":"Martinez, F. J. et al. Idiopathic pulmonary fibrosis. Nat. Rev. Dis. Prim. 3, 17074 (2017).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"3743_CR29","doi-asserted-by":"publisher","first-page":"1701209","DOI":"10.1183\/13993003.01209-2017","volume":"50","author":"G Raghu","year":"2017","unstructured":"Raghu, G. Idiopathic pulmonary fibrosis: lessons from clinical trials over the past 25 years. Eur. Respir. J. 50, 1701209 (2017).","journal-title":"Eur. Respir. J."},{"key":"3743_CR30","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1164\/ajrccm.164.7.2003140","volume":"164","author":"TE King","year":"2001","unstructured":"King, T. E., Tooze, J. A., Schwarz, M. I., Brown, K. R. & Cherniack, R. M. Predicting survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 164, 1171\u20131181 (2001).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"3743_CR31","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1183\/09031936.00174914","volume":"45","author":"L Wollin","year":"2015","unstructured":"Wollin, L. et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur. Respir. J. 45, 1434\u20131445 (2015).","journal-title":"Eur. Respir. J."},{"key":"3743_CR32","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.15420\/cfr.2021.30","volume":"8","author":"A Aimo","year":"2022","unstructured":"Aimo, A. et al. Pirfenidone for idiopathic pulmonary fibrosis and beyond. Card. Fail Rev. 8, e12 (2022).","journal-title":"Card. Fail Rev."},{"key":"3743_CR33","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","volume":"377","author":"PW Noble","year":"2011","unstructured":"Noble, P. W. et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 377, 1760\u20131769 (2011).","journal-title":"Lancet"},{"key":"3743_CR34","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","volume":"370","author":"L Richeldi","year":"2014","unstructured":"Richeldi, L. et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N. Engl. J. Med. 370, 2071\u20132082 (2014).","journal-title":"N. Engl. J. Med."},{"key":"3743_CR35","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","volume":"370","author":"TE King","year":"2014","unstructured":"King, T. E. et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 370, 2083\u20132092 (2014).","journal-title":"N. Engl. J. Med."},{"key":"3743_CR36","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.tips.2024.04.010","volume":"45","author":"CY Ewald","year":"2024","unstructured":"Ewald, C. Y. et al. TNIK\u2019s emerging role in cancer, metabolism, and age-related diseases. Trends Pharmacol. Sci. 45, 478\u2013489 (2024).","journal-title":"Trends Pharmacol. Sci."},{"key":"3743_CR37","doi-asserted-by":"publisher","first-page":"3961","DOI":"10.1021\/acs.jcim.3c01619","volume":"64","author":"P Kamya","year":"2024","unstructured":"Kamya, P. et al. PandaOmics: an AI-driven platform for therapeutic target and biomarker discovery. J. Chem. Inf. Model. 64, 3961\u20133969 (2024).","journal-title":"J. Chem. Inf. Model."},{"key":"3743_CR38","doi-asserted-by":"publisher","unstructured":"Su, C.-Y. et al. Multi-ancestry proteome-phenome-wide Mendelian randomization offers a comprehensive protein-disease atlas and potential therapeutic targets. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2024.10.17.24315553 (2024).","DOI":"10.1101\/2024.10.17.24315553"},{"key":"3743_CR39","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1164\/rccm.202301-0117OC","volume":"209","author":"JM Oldham","year":"2024","unstructured":"Oldham, J. M. et al. Proteomic biomarkers of survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 209, 1111\u20131120 (2024).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"3743_CR40","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1164\/rccm.201105-0840OC","volume":"184","author":"RM du Bois","year":"2011","unstructured":"du Bois, R. M. et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am. J. Respir. Crit. Care Med. 184, 1382\u20131389 (2011).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"3743_CR41","doi-asserted-by":"publisher","first-page":"17","DOI":"10.4187\/respcare.01435","volume":"57","author":"MC McCormack","year":"2012","unstructured":"McCormack, M. C. Facing the noise: addressing the endemic variability in DLCO testing. Respir. Care 57, 17\u201325 (2012).","journal-title":"Respir. Care"},{"key":"3743_CR42","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1164\/rccm.200703-463PP","volume":"176","author":"HR Collard","year":"2007","unstructured":"Collard, H. R. et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 176, 636\u2013643 (2007).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"3743_CR43","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1183\/09031936.00159709","volume":"37","author":"JW Song","year":"2011","unstructured":"Song, J. W., Hong, S.-B., Lim, C.-M., Koh, Y. & Kim, D. S. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur. Respir. J. 37, 356\u2013363 (2011).","journal-title":"Eur. Respir. J."},{"key":"3743_CR44","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1056\/NEJMoa2201737","volume":"386","author":"L Richeldi","year":"2022","unstructured":"Richeldi, L. et al. Trial of a preferential phosphodiesterase 4B inhibitor for idiopathic pulmonary fibrosis. N. Engl. J. Med. 386, 2178\u20132187 (2022).","journal-title":"N. Engl. J. Med."},{"key":"3743_CR45","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1164\/rccm.201010-1752OC","volume":"183","author":"SC Wootton","year":"2011","unstructured":"Wootton, S. C. et al. Viral infection in acute exacerbation of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 183, 1698\u20131702 (2011).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"3743_CR46","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1164\/rccm.201604-0801CI","volume":"194","author":"HR Collard","year":"2016","unstructured":"Collard, H. R. et al. Acute exacerbation of idiopathic pulmonary fibrosis. An International Working Group Report. Am. J. Respir. Crit. Care Med. 194, 265\u2013275 (2016).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"3743_CR47","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12931-015-0280-9","volume":"16","author":"A Sokai","year":"2015","unstructured":"Sokai, A. et al. Matrix metalloproteinase-10: a novel biomarker for idiopathic pulmonary fibrosis. Respir. Res. 16, 120 (2015).","journal-title":"Respir. Res."},{"key":"3743_CR48","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1042\/CS20180435","volume":"132","author":"Y Enomoto","year":"2018","unstructured":"Enomoto, Y. et al. LTBP2 is secreted from lung myofibroblasts and is a potential biomarker for idiopathic pulmonary fibrosis. Clin. Sci. 132, 1565\u20131580 (2018).","journal-title":"Clin. Sci."},{"key":"3743_CR49","doi-asserted-by":"publisher","first-page":"4809","DOI":"10.1007\/s10238-023-01214-x","volume":"23","author":"M Zou","year":"2023","unstructured":"Zou, M. et al. Plasma LTBP2 as a potential biomarker in differential diagnosis of connective tissue disease-associated interstitial lung disease and idiopathic pulmonary fibrosis: a pilot study. Clin. Exp. Med. 23, 4809\u20134816 (2023).","journal-title":"Clin. Exp. Med."},{"key":"3743_CR50","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1007\/s00345-013-1077-4","volume":"31","author":"D Shang","year":"2013","unstructured":"Shang, D., Xu, X., Wang, D., Li, Y. & Liu, Y. Protein tyrosine phosphatase \u03b6 enhances proliferation by increasing \u03b2-catenin nuclear expression in VHL-inactive human renal cell carcinoma cells. World J. Urol. 31, 1547\u20131554 (2013).","journal-title":"World J. Urol."},{"key":"3743_CR51","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/S0002-9440(10)64282-4","volume":"162","author":"M Chilosi","year":"2003","unstructured":"Chilosi, M. et al. Aberrant Wnt\/\u03b2-catenin pathway activation in idiopathic pulmonary fibrosis. Am. J. Pathol. 162, 1495\u20131502 (2003).","journal-title":"Am. J. Pathol."},{"key":"3743_CR52","doi-asserted-by":"publisher","first-page":"829673","DOI":"10.3389\/fphar.2022.829673","volume":"13","author":"X Hu","year":"2022","unstructured":"Hu, X. et al. Dec1 deficiency ameliorates pulmonary fibrosis through the PI3K\/AKT\/GSK-3\u03b2\/\u03b2-catenin integrated signaling pathway. Front. Pharmacol. 13, 829673 (2022).","journal-title":"Front. Pharmacol."},{"key":"3743_CR53","doi-asserted-by":"publisher","first-page":"10004","DOI":"10.3390\/ijms241210004","volume":"24","author":"H Devos","year":"2023","unstructured":"Devos, H., Zoidakis, J., Roubelakis, M. G., Latosinska, A. & Vlahou, A. Reviewing the regulators of COL1A1. Int. J. Mol. Sci. 24, 10004 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"3743_CR54","first-page":"7105","volume":"17","author":"E Bibaki","year":"2018","unstructured":"Bibaki, E. et al. miR-185 and miR-29a are similarly expressed in the bronchoalveolar lavage cells in IPF and lung cancer but common targets DNMT1 and COL1A1 show disease specific patterns. Mol. Med. Rep. 17, 7105\u20137112 (2018).","journal-title":"Mol. Med. Rep."},{"key":"3743_CR55","doi-asserted-by":"publisher","first-page":"711239","DOI":"10.3389\/fmolb.2021.711239","volume":"8","author":"H Wan","year":"2021","unstructured":"Wan, H. et al. Identification of Hub genes and pathways associated with idiopathic pulmonary fibrosis via bioinformatics analysis. Front. Mol. Biosci. 8, 711239 (2021).","journal-title":"Front. Mol. Biosci."},{"key":"3743_CR56","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1165\/rcmb.2021-0257OC","volume":"66","author":"S Huang","year":"2022","unstructured":"Huang, S. et al. Asporin promotes TGF-\u03b2\u2013induced lung myofibroblast differentiation by facilitating Rab11-dependent recycling of T\u03b2RI. Am. J. Respir. Cell Mol. Biol. 66, 158\u2013170 (2022).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"3743_CR57","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jprot.2018.02.027","volume":"189","author":"E \u00c5hrman","year":"2018","unstructured":"\u00c5hrman, E. et al. Quantitative proteomic characterization of the lung extracellular matrix in chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. J. Proteom. 189, 23\u201333 (2018).","journal-title":"J. Proteom."},{"key":"3743_CR58","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00408-021-00505-y","volume":"200","author":"JL Todd","year":"2022","unstructured":"Todd, J. L. et al. Association of circulating proteins with death or lung transplant in patients with idiopathic pulmonary fibrosis in the IPF-PRO Registry Cohort. Lung 200, 11\u201318 (2022).","journal-title":"Lung"},{"key":"3743_CR59","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.humpath.2005.11.020","volume":"37","author":"PS Acharya","year":"2006","unstructured":"Acharya, P. S., Zukas, A., Chandan, V., Katzenstein, A.-L. A. & Pur\u00e9, E. Fibroblast activation protein: a serine protease expressed at the remodeling interface in idiopathic pulmonary fibrosis. Hum. Pathol. 37, 352\u2013360 (2006).","journal-title":"Hum. Pathol."},{"key":"3743_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2022.121960","volume":"293","author":"ET Hoffman","year":"2023","unstructured":"Hoffman, E. T. et al. Regional and disease specific human lung extracellular matrix composition. Biomaterials 293, 121960 (2023).","journal-title":"Biomaterials"},{"key":"3743_CR61","doi-asserted-by":"publisher","first-page":"72650","DOI":"10.1186\/ar-2001-72650","volume":"3","author":"L Shum","year":"2001","unstructured":"Shum, L. Chondroadherin binds to type II collagen. Arthritis Res. Ther. 3, 72650 (2001).","journal-title":"Arthritis Res. Ther."},{"key":"3743_CR62","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","volume":"205","author":"G Raghu","year":"2022","unstructured":"Raghu, G. et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am. J. Respir. Crit. Care Med. 205, e18\u2013e47 (2022).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"3743_CR63","doi-asserted-by":"publisher","first-page":"e70","DOI":"10.1164\/rccm.201908-1590ST","volume":"200","author":"BL Graham","year":"2019","unstructured":"Graham, B. L. et al. Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement. Am. J. Respir. Crit. Care Med. 200, e70\u2013e88 (2019).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"3743_CR64","doi-asserted-by":"publisher","first-page":"1600016","DOI":"10.1183\/13993003.00016-2016","volume":"49","author":"BL Graham","year":"2017","unstructured":"Graham, B. L. et al. 2017 ERS\/ATS standards for single-breath carbon monoxide uptake in the lung. Eur. Respir. J. 49, 1600016 (2017).","journal-title":"Eur. Respir. J."},{"key":"3743_CR65","doi-asserted-by":"publisher","unstructured":"Birring, S. S. et al. Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ). Thorax https:\/\/doi.org\/10.1136\/thorax.58.4.339 (2003).","DOI":"10.1136\/thorax.58.4.339"},{"key":"3743_CR66","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2147\/COPD.S219480","volume":"15","author":"P Rebelo","year":"2020","unstructured":"Rebelo, P. et al. Minimal clinically important differences for patient-reported outcome measures of cough and sputum in patients with COPD. Int J. Chron. Obstruct. Pulmon. Dis. 15, 201\u2013212 (2020).","journal-title":"Int J. Chron. Obstruct. Pulmon. Dis."},{"key":"3743_CR67","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1477-7525-10-4","volume":"10","author":"FF Berkhof","year":"2012","unstructured":"Berkhof, F. F. et al. The validity and precision of the Leicester Cough Questionnaire in COPD patients with chronic cough. Health Qual. Life Outcomes 10, 4 (2012).","journal-title":"Health Qual. Life Outcomes"},{"key":"3743_CR68","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1183\/09031936.00160508","volume":"34","author":"MP Murray","year":"2009","unstructured":"Murray, M. P., Turnbull, K., MacQuarrie, S., Pentland, J. L. & Hill, A. T. Validation of the Leicester Cough Questionnaire in non-cystic fibrosis bronchiectasis. Eur. Respir. J. 34, 125\u2013131 (2009).","journal-title":"Eur. Respir. J."},{"key":"3743_CR69","doi-asserted-by":"publisher","first-page":"175346662210997","DOI":"10.1177\/17534666221099737","volume":"16","author":"AM Nguyen","year":"2022","unstructured":"Nguyen, A. M. et al. Leicester Cough Questionnaire validation and clinically important thresholds for change in refractory or unexplained chronic cough. Ther. Adv. Respir. Dis. 16, 17534666221099737 (2022).","journal-title":"Ther. Adv. Respir. Dis."},{"key":"3743_CR70","doi-asserted-by":"publisher","first-page":"D672\u2013D678","DOI":"10.1093\/nar\/gkad1025","volume":"52","author":"M Milacic","year":"2024","unstructured":"Milacic, M. et al. The Reactome Pathway Knowledgebase 2024. Nucleic Acids Res. 52, D672\u2013D678 (2024).","journal-title":"Nucleic Acids Res."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03743-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03743-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03743-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T17:27:52Z","timestamp":1757179672000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03743-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,3]]},"references-count":70,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["3743"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-03743-2","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,3]]},"assertion":[{"value":"19 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"F.R., S.R., C.S., S.L., Y.L., H.Z., S.C., H.C., M.K., D.G. and A.Z. are employees of Insilico Medicine. Insilico Medicine was the study sponsor. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}